Bay­er re­calls one lot of sol­id tu­mor drug Vi­t­rakvi af­ter find­ing mi­cro­bial con­t­a­m­i­na­tion

Bay­er is vol­un­tar­i­ly re­call­ing a batch of its oral sol­id tu­mor drug Vi­t­rakvi be­cause of mi­cro­bial con­t­a­m­i­na­tion, just weeks af­ter with­draw­ing a sep­a­rate fol­lic­u­lar lym­phoma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA